Table 1 Demographic and clinical characteristics of the study population according to treatment group on day 0.
Artesunate-amodiaquine N = 360 | Artesunate-mefloquine N = 145 | Artemether-lumefantrine (four-doses) N = 140 | Artemether-lumefantrine (six-doses) N = 149 | Amodiaquine-sulphadoxine-pyrimethamine N = 161 | |
|---|---|---|---|---|---|
Mean age (yrs) | 15 | 15 | 12 | 13 | 12 |
Range | 1–75 | 2–65 | 2–63 | 2–60 | 2–51 |
Mean wt (kg) | 36 | 37 | 32 | 35 | 37 |
Range | 5–102 | 11–110 | 12–83 | 6–89 | |
Mean Parasitaemia (parasites/μL) | 39800 | 27000 | 22000 | 15398 | 27000 |
Hb < 12 g/dL | 68.6% | 62.5% | 96.7% | 68.6% | 70.3% |
SGOT > 30 UI/L | 15.2% | 0% | 9.7% | 17.1% | 0% |
SGPT > 35 UI/L | 0% | 0% | 0% | 2.8% | 0% |
Creatininemia > 14 mg/L | 0% | 0% | 0% | 30% | 0% |